NCT04699838

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Muhammad Furqan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.

Conditions

• Extensive Stage Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Cisplatin	Cisplatin
DRUG	Carboplatin	Carboplatin
DRUG	Etoposide	Etoposide
DRUG	Durvalumab	Durvalumab
DRUG	Ceralasertib	Ceralasertib

Timeline

• Start date: 2021-04-20
• Primary completion: 2026-03-01
• Completion: 2026-11-01
• First posted: 2021-01-07
• Last updated: 2026-01-02

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study